Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 1
2010 1
2011 3
2012 2
2015 1
2016 2
2019 1
2020 1
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.
Zachariah NN, Basu A, Gautam N, Ramamoorthi G, Kodumudi KN, Kumar NB, Loftus L, Czerniecki BJ. Zachariah NN, et al. Among authors: kodumudi kn. Front Immunol. 2021 Nov 24;12:786286. doi: 10.3389/fimmu.2021.786286. eCollection 2021. Front Immunol. 2021. PMID: 34899753 Free PMC article.
Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.
Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Jia Y, et al. Among authors: kodumudi kn. Mol Ther. 2021 Apr 7;29(4):1541-1556. doi: 10.1016/j.ymthe.2020.12.037. Epub 2021 Jan 5. Mol Ther. 2021. PMID: 33412308 Free article.
Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.
Bunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Bunch BL, et al. Among authors: kodumudi kn. Cancer Immunol Immunother. 2020 Dec;69(12):2465-2476. doi: 10.1007/s00262-020-02634-4. Epub 2020 Jun 18. Cancer Immunol Immunother. 2020. PMID: 32556443 Free PMC article.
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.
Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Pilon-Thomas S, et al. Among authors: kodumudi kn. Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30. Cancer Res. 2016. PMID: 26719539 Free PMC article.
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine.
Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Duckett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, Soliman H, Lee MC, Kalinski P, Czerniecki BJ. Basu A, et al. Among authors: kodumudi kn. Cancer Immunol Res. 2022 Jan;10(1):108-125. doi: 10.1158/2326-6066.CIR-21-0454. Epub 2021 Nov 16. Cancer Immunol Res. 2022. PMID: 34785506
Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, Greene MI, Costa RLB, Czerniecki BJ. Kodumudi KN, et al. Front Immunol. 2019 Aug 14;10:1939. doi: 10.3389/fimmu.2019.01939. eCollection 2019. Front Immunol. 2019. PMID: 31475002 Free PMC article.
15 results